Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

INAPITANT TRI-PACK CAPSULE [SIN16363P]

Active ingredients: APREPITANT (125 MG CAPSULE) | APREPITANT (80 MG CAPSULE)

View product's general information
Last updated on 9 October 2026

Product Info

INAPITANT TRI-PACK CAPSULE

[SIN16363P]

Product information

Active Ingredient and Strength

APREPITANT (125 MG CAPSULE) - 125 MG
APREPITANT (80 MG CAPSULE) - 80 MG

Dosage Form

CAPSULE

Manufacturer and Country

PHARMATHEN INTERNATIONAL SA - GREECE

Registration Number

SIN16363P

Licence Holder

INTEGA PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

A04AD12

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications
INAPITANT is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:

  • Highly emetogenic cancer chemotherapy

  • Moderately emetogenic cancer chemotherapy

INAPITANT should be given in combination with a corticosteroid and a 5-HT3 antagonist.

Dosing

4.2 Posology and method of administration
INAPITANT is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose of INAPITANT is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. The package insert for the co-administered 5-HT3 antagonist must be consulted prior to initiation of treatment with INAPITANT.

INAPITANT has not been studied for the treatment of established nausea and vomiting.

Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:

Inapitant Dosage Table 1



Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:

Inapitant Dosage Table 2



Chronic continuous administration is not recommended.

See 4.5 for additional information on the administration of INAPITANT with corticosteroids – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Refer to the full prescribing information for co-administered antiemetic agents.

INAPITANT may be taken with or without food.

No dosage adjustment is necessary based on age, gender, race or Body Mass Index (BMI).

No dosage adjustment is necessary for patients with severe renal insufficiency (creatinine clearance <30 mL/min) or for patients with end stage renal disease undergoing hemodialysis.

No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic insufficiency (Child-Pugh score >9).

Contraindications

4.3 Contraindications
Aprepitant is contraindicated in patients who are hypersensitive to any component of the product. Aprepitant should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4) by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions (see 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).